Ernexa Therapeutics Inc. (ERNA)
| Market Cap | 10.36M |
| Revenue (ttm) | 1,000 |
| Net Income (ttm) | -18.36M |
| Shares Out | 7.85M |
| EPS (ttm) | -3.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,742 |
| Open | 1.300 |
| Previous Close | 1.310 |
| Day's Range | 1.201 - 1.320 |
| 52-Week Range | 1.090 - 14.400 |
| Beta | 6.72 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 7, 2025 |
About ERNA
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. ... [Read more]
Financial Performance
In 2024, Ernexa Therapeutics's revenue was $582,000, an increase of 755.88% compared to the previous year's $68,000. Losses were -$44.56 million, 105.5% more than in 2023.
Financial StatementsNews
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting
CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune diseas...
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.
Appointment reinforces clinical and translational depth as Ernexa advances its best-in-class iMSC cell therapy platform into first-in-human trials Appointment reinforces clinical and translational dep...
Ernexa Therapeutics to Present at Oxford Global's Cell 2025
CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune diseas...
Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials
The Company's operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence
Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform
Access the “What This Means” segment here CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatme...
Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer
THE WOODLANDS, Texas, and CAMBRIDGE, Mass. , Oct. 29, 2025 /PRNewswire/ -- Cellipont Bioservices , a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced it...
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announce...
Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit
CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announc...
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
Presentation to highlight preclinical data from the company's lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trials Pr...
Ernexa Therapeutics Provides Update on Operational Excellence and Performance
CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today provide...
Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disea...
Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announ...
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa's Strategic Focus on Ovarian Cancer and Autoimmune Disease Programs Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa'...
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiatives Stockholder-approved financing brings total gross proceeds to $7.1 million; fun...
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announce...
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomes New data finds novel cell therapy succe...
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced...
Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference
Cambridge, Massachusetts--(Newsfile Corp. - May 8, 2025) - Ernexa Therapeutics (NASDAQ: ERNA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 1...
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented not...
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
Conference attendees will get first look at new data that supports the potential of ERNA-101 to boost anti-tumor immunity in ovarian cancer Conference attendees will get first look at new data that su...
Ernexa Therapeutics Closes New Funding Round
Comes on the heels of company's rebranding and new strategic direction, advancing its lead program in ovarian cancer Comes on the heels of company's rebranding and new strategic direction, advancing i...
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
Meeting addressed progress and strategic direction for company's induced mesenchymal stem cell (iMSC) therapy programs Meeting addressed progress and strategic direction for company's induced mesenchy...
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
New data from proof-of-concept study provides roadmap for treatment of ovarian cancer.
Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna's lead indication in ovarian cancer World-renowned researcher brings expertise in obstetr...
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) announced today that it has regained compliance with Nasdaq for continued listin...